Search
Selected Filter
Displaying 11–20 of 230 research results
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
The approach holds potential for restoring vision to people with little or no vision
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
More than 8,000 people have applied for genetic testing through the Foundation’s program
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
His latest Foundation grant is helping move the drug toward a clinical trial
-
Are You on the Clinical Trial Radar Screen?
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
The company plans to enroll additional patients as young as four years old
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
